Australia/NZ Healthcare: What are we hearing in ANZ healthcare? – October 2026

This note summarises the most and least debated names in Citi's Australia/NZ healthcare coverage over the past month. Most talked about: CSL signed a co-develop/co-promote deal with Swiss biotech Alentis, seen as a positive step to restock the pipeline in an area of commercial expertise (renal disease), though harder without a permanent CEO; CSL will also transition back to Haemonetics' plasmapheresis system by end-2027, with no payment from CSL for terminating the Terumo Rika arrangement, and the next major catalyst is appointment of a new CEO after the 27 October AGM. Investor questions on the Telix/ITM deal centred on valuation and its split between the existing lutetium business and ITM-11;